Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: Can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?

Journal of Gastroenterology

Volumn 47, Issue 11, 2012, Pages 1238-1247

  Shigefuku, Ryuta ^a   Takahashi, Hideaki ^a   Kobayashi, Minoru ^a   Ikeda, Hiroki ^a   Matsunaga, Kotaro ^a   Okuse, Chiaki ^a   Matsumoto, Nobuyuki ^a   Maeyama, Shiro ^b   Sase, Shigeru ^c   Suzuki, Michihiro ^a   Itoh, Fumio ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shiodome Medical Examination Clinic   (Japan)

^c Anzai Medical Company Ltd (SS)   (Japan)

Author keywords

Hepatic tissue blood flow; Nonalcoholic steatohepatitis; Simple steatosis; Xenon computed tomography

Indexed keywords

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; LIVER BLOOD FLOW; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; SIMPLE STEATOSIS; XENON COMPUTED TOMOGRAPHY;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; SEVERITY OF ILLNESS INDEX; SOLUBILITY; TOMOGRAPHY, X-RAY COMPUTED; XENON; YOUNG ADULT;

EID: 84872262423     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0581-4     Document Type: Article

References (53)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8.
2. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283-98.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.
4. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954-61.
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37(5):1202-19.
6. Ikeda H, Suzuki M, Kobayashi M, Takahashi H, Matsumoto N, Maeyama S, et al. Xenon computed tomography shows hemodynamic change during the progression of chronic hepatitis C. Hepatol Res. 2007;37(2):104-12.
7. Kobayashi M, Suzuki M, Ikeda H, Takahashi H, Matsumoto N, Maeyama S, et al. Assessment of hepatic steatosis and hepatic tissue blood flow by xenon computed tomography in nonalcoholic steatohepatitis. Hepatol Res. 2009;39(1):31-9.
8. Hayashi S, Dono K, Shimizu J, Murakami T, Takamura M, Kim T, et al. New measurement of hepatic blood flow by xenon CT system: an animal study with PGE1. J Surg Res. 2005;129:24-30.
9. Hashimoto K, Murakami T, Dono K, Hori M, Kim T, Kudo M, et al. Quantitative tissue blood flow measurement of the liver parenchyma: comparison between xenon CT and perfusion CT. Dig Dis Sci. 2007;52:943-9.
10. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467-74.
11. Andersen AM, Ladefoged J. Partition coefficient of 133-xenon between various tissues and blood in vivo. Scand J Clin Lab Invest. 1967;19:72-8.
12. Steward A, Allott PR, Cowles AL, Mapleson WW. Solubility coefficients for inhaled anaesthetics for water, oil and biological media. Br J Anaesth. 1973;45(3):282-93.
13. Sase S, Monden M, Oka H, Dono K, Fukuta T, Shibata I. Hepatic blood flow measurements with arterial and portal blood flow mapping in the human liver by means of xenon CT. J Comput Assist Tomogr. 2002;26:243-9.
14. Sase S, Takahashi H, Ikeda H, Kobayashi M, Matsumoto N, Suzuki M. Determination of time-course change rate for arterial xenon using the time course of tissue xenon concentration in xenonenhanced computed tomography. Med Phys. 2008;35:2331-8.
15. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-21.
16. Dam-Larsen S, Becker U, FranzmannMB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009;44(10):1236-43.
17. EkstedtM, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients withNAFLDand elevated liver enzymes. Hepatology. 2006;44(4):865-73.
18. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98(9):2042-7.
19. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology. 2010;51(2):373-5.
20. Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol. 2002;55(9):689-92.
21. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234-8.
22. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595-602.
23. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology. 2006;44(4):874-80.
24. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898-906.
25. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35(6):1485-93.
26. Gulberg V, Haag K, Rossle M, Gerbes AL. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology. 2002;35(3):630-4.
27. Richter S, Mucke I, Menger MD, Vollmar B. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. Am J Physiol Gastrointest Liver Physiol. 2000;279(2):G454-62.
28. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (Fibro- Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6.
29. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54.
30. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-12.
31. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91-100.
32. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26(2):151-6.
33. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34.
34. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102(2):399-408.
35. Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47(6):1916-23.
36. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-50.
37. Obara N, Ueno Y, Fukushima K, Nakagome Y, Kakazu E, Kimura O, et al. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol. 2008;43(9):720-8.
38. Yoneda M, Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56(9):1330-1.
39. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40(5):371-8.
40. Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010;256(2):640-7.
41. Kikuchi M, Tomita K, Nakahara T, Kitamura N, Teratani T, Irie R, et al. Utility of quantitative 99mTc-phytate scintigraphy to diagnose early-stage non-alcoholic steatohepatitis. Scand J Gastroenterol. 2009;44(2):229-36.
42. Iijima H, Moriyasu F, Tsuchiya K, Suzuki S, Yoshida M, Shimizu M, et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res. 2007;37(9):722-30.
43. Seifalian AM, El-Desoky A, Davidson BR. Hepatic indocyanine green uptake and excretion in a rabbit model of steatosis. Eur Surg Res. 2001;33:193-201.
44. Hayashi N, Kasahara A, Kurosawa K, Sasaki Y, Fusamoto H, Sato N, et al. Oxygen supply to the liver in patients with alcoholic liver disease assessed by organ-reflectance spectrophotometry. Gastroenterology. 1985;88(4):881-6.
45. Takahashi H, Suzuki M, Ikeda H, Kobayashi M, Sase S, Yotsuyanagi H, et al. Evaluation of quantitative portal venous, hepatic arterial, and total hepatic tissue blood flow using xenon CT in alcoholic liver cirrhosis-comparison with liver cirrhosis related to hepatitis C virus and nonalcoholic steatohepatitis. Alcohol Clin Exp Res. 2010;34:S7-13.
46. Takahashi H, Suzuki M, Ikeda H, Kobayashi M, Sase S, Yotsuyanagi H, et al. Evaluation of quantitative portal venous, hepatic arterial, and total hepatic tissue blood flow using xenon CT in alcoholic liver cirrhosis: comparison with liver cirrhosis C. Alcohol Clin Exp Res. 2007;31:S43-8.
47. Seifalian AM, Piasecki C, Agarwal A, Davidson BR. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation. 1999;68:780-4.
48. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology. 2004;40(2): 386-93.
49. Pasarin M, Abraldes JG, Rodriguez-Vilarrupla A, La Mura V, Garcia-Pagan JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol. 2011;55(5): 1095-102.
50. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114(4):842-5.
51. Mitsuoka H, Suzuki S, Sakaguchi T, Baba S, Miwa M, Konno H, et al. Contribution of endothelin-1 to microcirculatory impairment in total hepatic ischemia and reperfusion injury. Transplantation. 1999;67(4):514-20.
52. Katagiri H, Ito Y, Ito S, Murata T, Yukihiko S, Narumiya S, et al. TNF-alpha induces thromboxane receptor signaling-dependent microcirculatory dysfunction in mouse liver. Shock. 2008;30(4): 463-7.
53. Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev. 2009;89(4):1269-339.